Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin
Sponsor: Mesoblast, Ltd.
Listed as NCT01576328, this PHASE1/PHASE2 trial focuses on Type 2 Diabetes and remains completed. Sponsored by Mesoblast, Ltd., it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jul 2020 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Mar 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mesoblast, Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .